U.S. pharmaceutical giant Pfizer
signed an agreement (NYT) to share the recipe for its COVID-19 treatment pill with manufacturers in ninety-five developing countries, mostly in Africa and Asia. The company said the drug
can reduce risk of hospitalization or death (WaPo) from the coronavirus by as much as 89 percent.
Global health experts praised the deal, which follows a similar agreement by pharmaceutical firm Merck and comes as many countries struggle with low vaccination rates and high caseloads. Still, some health advocates
criticized Pfizer’s exclusion (NPR) of hard-hit, middle-income countries such as Brazil and Russia, as well as its refusal to give poorer countries the formula for its COVID-19 vaccine even as they receive the fewest doses of the shots.